Tocotrienols for Fatty Liver (NAFLD): What the Trials Show

By Erin Rose · Updated July 19, 2026 · Methodology

Educational overview — not medical advice. Tocotrienols are not an approved or proven treatment for nonalcoholic fatty liver disease (NAFLD); alpha-tocopherol, not tocotrienol, is the vitamin E form referenced in NAFLD clinical guidance. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

The core positive trial, read carefully

Pervez 2020 is the single best-designed positive NAFLD RCT in this evidence base: a double-blind, placebo-controlled trial in 71 NAFLD patients (35 tocotrienol, 36 placebo) at the Armed Forces Institute of Pathology in Rawalpindi, Pakistan, dosing delta-tocotrienol 300mg twice daily (600mg/day total) for 24 weeks. Both stated primary endpoints were met: fatty liver index fell by a mean difference of −8.52 (95% CI −10.7 to −6.3, p<0.001) and HOMA-IR fell −0.37 (p<0.001), with secondary markers — hs-CRP, malondialdehyde, ALT, AST, and ultrasound steatosis grade — all significantly improved too, and no adverse events reported. It's a real, well-designed positive result. The honest caveat: it's one trial from one group, not yet independently replicated by a lab without ties to the same research team.

The head-to-head trial: equivalent, not superior

The same Rawalpindi group ran a more demanding test: Pervez 2022 compared delta-tocotrienol (300mg twice daily) directly against alpha-tocopherol (268mg twice daily) — the vitamin E form actually used in NAFLD clinical practice — in a double-blind, active-controlled RCT with no placebo arm, 100 patients (50/50), over 48 weeks. All three stated primary endpoints (change in fatty liver index, liver-to-spleen CT attenuation ratio, and HOMA-IR) showed "a significant improvement (p<.001) ... in both groups ... that was not significant between the two groups." Read plainly: on the endpoints the trial was actually designed to test, delta-tocotrienol did not beat the standard vitamin E form already used for this condition — it matched it. Delta-tocotrienol did show a real advantage on several secondary markers — body weight, IL-6, TNF-alpha, leptin, cytokeratin-18, and adiponectin (p<0.05) — and a companion microRNA sub-analysis of the same cohort (Pervez 2023) found delta-tocotrienol outperformed alpha-tocopherol specifically on two circulating microRNAs (miR-375, miR-34a) linked to inflammation and apoptosis. Those are real findings, but they're secondary results layered onto a primary-endpoint tie, and the microRNA analysis is the same underlying cohort, not independent replication.

One more structural caveat on both Pervez trials: neither has a true independent replication outside this one research group, and the active-controlled design (no placebo arm in the head-to-head trial) means diet and lifestyle counseling given alongside 48 weeks of supplementation can't be fully separated from the supplement's own effect.

The pediatric trial: a genuine, useful counterweight

The one trial testing tocotrienol in children tells a different, more cautionary story. Al-Baiaty 2024 ran a single-blind RCT in 29 obese children and adolescents (ages 10-18) with NAFLD, dosing tocotrienol-rich fraction 50mg/day for 6 months. ApoA-1 and AST improved significantly in the tocotrienol group (p=0.002, p=0.038), along with DNA damage and inflammatory cytokine markers. But on the trial's actual imaging measure of fatty liver — hepatic steatosis on FibroScan/CAP — the result ran backwards: steatosis "was significantly reduced in the placebo group ... but not in the TRF group." That's the primary measure of the disease itself improving more without the supplement. The trial is small (n=29) and single-blind, and one co-author is affiliated with a Malaysian palm-oil company (Sime Darby Oils Nutrition) — disclosed here, as with every industry tie in this evidence base — but the steatosis result is exactly the kind of honesty counterweight that belongs in any NAFLD claim about tocotrienols, especially for children.

What the systematic review says, and who wrote it

The field's main synthesis paper, Chin 2023, reviewed 12 articles (8 animal, 4 human) through October 2022 and concluded that "T3 isomers or natural mixtures (derived from palm or annatto) improved NAFLD outcomes (liver histology, ultrasound or liver profile). However, the improvement depended on the severity of NAFLD, study period and type of intervention." That's a real but qualified positive conclusion — and it carries a direct conflict of interest worth stating every time it's cited: co-author Anne Trias is a named employee of American River Nutrition, the manufacturer of DeltaGold annatto tocotrienol, the dominant branded ingredient in this category. The review discloses this ("the employer did not have a part in the planning and writing of this review"), but it remains a direct industry co-authorship on the field's central synthesis paper.

Verified tocotrienols products

If you and your clinician are weighing this as an adjunct, here's how the tocotrienols products we track and verify compare on sourcing and cost.

Frequently asked questions

Related

• Tocotrienols: what they are & the honest evidence
• Tocotrienols vs Tocopherols — the cholesterol-claim timeline
• Dosage Guide — the 600mg/day NAFLD trial dose in context
• Best Tocotrienols — ranked by sourcing disclosure & cost
• Does Citrus Bergamot Actually Lower Cholesterol? — the same industry-linked-trials-vs-independent-evidence pattern

Sources